MX9706785A - Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato. - Google Patents

Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.

Info

Publication number
MX9706785A
MX9706785A MX9706785A MX9706785A MX9706785A MX 9706785 A MX9706785 A MX 9706785A MX 9706785 A MX9706785 A MX 9706785A MX 9706785 A MX9706785 A MX 9706785A MX 9706785 A MX9706785 A MX 9706785A
Authority
MX
Mexico
Prior art keywords
proton pump
pump inhibitor
alginate
dosage forms
oral pharmaceutical
Prior art date
Application number
MX9706785A
Other languages
English (en)
Inventor
Helene Depui
Agneta Hallgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9706785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of MX9706785A publication Critical patent/MX9706785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

Una forma de dosis farmacéutica oral que comprende un inhibidor de la bomba de protones susceptible al ácido y uno más agentes antiácidos como un alginato en una formulacion fija, donde al inhibidor de la bomba de protones se protegio con una capa de revestimiento entérico y una capa de separamiento enteríco y una capa de separamiento opcional entre el inhibidor de la bomba de protones y el revestimiento entérico. La formulacion fija en la tabletas multicapas, saquitos o formas de dosis de tabletas multiple. La forma de dosis de unidad multiple es más preferida. La nueva formulacion fija es especialmente util en el tratamiento de enfermedades asociadas dispepsia tal como la acidez.
MX9706785A 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato. MX9706785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I
PCT/SE1996/001737 WO1997025066A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Publications (1)

Publication Number Publication Date
MX9706785A true MX9706785A (es) 1997-11-29

Family

ID=20400969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706785A MX9706785A (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.

Country Status (35)

Country Link
US (1) US6183776B1 (es)
EP (1) EP0813424B2 (es)
JP (1) JPH11501950A (es)
KR (1) KR100490075B1 (es)
CN (1) CN1080125C (es)
AR (1) AR005281A1 (es)
AT (1) ATE228009T1 (es)
AU (1) AU712669B2 (es)
BR (1) BR9607350B1 (es)
CA (1) CA2213996C (es)
CZ (1) CZ293583B6 (es)
DE (1) DE69624907T3 (es)
DK (1) DK0813424T4 (es)
EE (1) EE04002B1 (es)
EG (1) EG23821A (es)
ES (1) ES2185817T5 (es)
HK (2) HK1001763A1 (es)
HU (1) HU229153B1 (es)
IL (1) IL121651A (es)
IS (1) IS2716B (es)
MX (1) MX9706785A (es)
MY (1) MY116091A (es)
NO (1) NO326656B1 (es)
NZ (1) NZ325977A (es)
PL (1) PL187075B1 (es)
PT (1) PT813424E (es)
RU (1) RU2179453C2 (es)
SA (1) SA97170553B1 (es)
SE (1) SE9600071D0 (es)
SK (1) SK283695B6 (es)
TR (1) TR199700916T1 (es)
TW (1) TW464514B (es)
UA (1) UA45392C2 (es)
WO (1) WO1997025066A1 (es)
ZA (1) ZA9610935B (es)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
MX9703918A (es) * 1997-05-28 1998-11-30 J Marshall M D Barry Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
FR2774906B1 (fr) * 1998-02-13 2000-05-12 Rhodia Chimie Sa Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
ES2237121T3 (es) 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
WO2000057838A2 (en) * 1999-03-29 2000-10-05 American Home Products Corporation Coating system
AU6087100A (en) * 1999-07-12 2001-01-30 Smithkline Beecham Corporation Heartburn treatment
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
MXPA04000385A (es) * 2001-07-16 2004-05-04 Astrazeneca Ab FORMULACION FARMACeUTICA QUE COMPRENDE INHIBIDOR DE LA BOMBA DE PROTONES Y ANTIaCIDOS.
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
ATE404179T1 (de) 2001-09-28 2008-08-15 Mcneil Ppc Inc Darreichungsformen mit kern und äusserer hülle
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7008777B2 (en) 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
KR100479637B1 (ko) * 2002-02-01 2005-03-31 한국화학연구원 란소프라졸을 함유하는 경구제제 및 그의 제조방법
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
KR101061351B1 (ko) 2002-04-09 2011-08-31 플라멜 테크놀로지스 활성 성분 마이크로캡슐의 경구 현탁액
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
US6663892B1 (en) * 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP2596792A1 (en) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7258981B2 (en) * 2003-01-24 2007-08-21 Clontech Laboratories, Inc. Sensitive proteasome sensor constructs and methods for their design and use
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
EP1759692A3 (en) * 2003-03-10 2007-09-12 Novartis AG Taste-masked solid veterinary compositions
JP4669391B2 (ja) * 2003-03-18 2011-04-13 興和株式会社 制酸剤組成物
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
EP1648417A4 (en) * 2003-07-18 2010-01-20 Santarus Inc PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF GASTROINTESTINAL ACIDITY RELATED DISORDERS
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060165793A1 (en) * 2003-08-04 2006-07-27 Koji Ukai Pharmaceutical preparation to be dispersed before administration
US7252665B2 (en) * 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US7282050B2 (en) * 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7041124B2 (en) * 2003-12-23 2006-05-09 Kimberly-Clark Worldwide, Inc. System and method for providing therapy to a portion of a body
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) * 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
SE530605C2 (sv) * 2005-09-29 2008-07-15 Barbara Nelson Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ZA200805646B (en) * 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN101259140B (zh) * 2007-03-08 2012-08-22 重庆北碚现代应用药物研究所 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法
BRPI0721654B8 (pt) * 2007-05-07 2022-07-05 Evonik Roehm Gmbh formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
UY33173A (es) * 2010-01-08 2011-07-29 Eurand Inc
CA2795521A1 (en) 2010-04-23 2011-10-27 S-Biotek Holding Aps A solid pharmaceutical composition for neutralizing stomach acid
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US20150238514A1 (en) * 2014-02-21 2015-08-27 William Armstrong Protective Supplement Configuration
US20170042806A1 (en) * 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2016404808A1 (en) * 2016-04-29 2018-12-13 Alan Thompson Veterinary composition
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201723199A2 (tr) * 2017-12-30 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Yeni farmasötik bileşimler.
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) * 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102146395B1 (ko) * 2018-08-23 2020-08-20 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
US20240100087A1 (en) * 2019-10-17 2024-03-28 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising proton pump inhibitor and antacid
MX2022009121A (es) * 2020-01-23 2022-08-18 Hanmi Pharm Ind Co Ltd Formulacion farmaceutica compuesta que comprende un inhibidor de la bomba de protones y un antiacido.
CN114980867B (zh) * 2020-01-23 2024-03-15 韩美药品株式会社 包含质子泵抑制剂和抗酸剂的药物复合制剂
KR102608889B1 (ko) * 2020-07-14 2023-12-04 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
KR20230097346A (ko) * 2021-12-24 2023-07-03 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
IE59287B1 (en) 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
US4568560A (en) 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
AU594424B2 (en) 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
US5112813A (en) 1986-03-07 1992-05-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Process for the preparation of a viscosity-stable antacid composition
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DK179687D0 (da) 1987-04-08 1987-04-08 Farma Food As Praeparat
EP0294933B1 (en) † 1987-05-08 1992-03-11 Smith Kline & French Laboratories Limited Pharmaceutical compositions
KR960011236B1 (ko) † 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
NZ230701A (en) 1988-09-20 1992-01-29 Glaxo Group Ltd Pharmaceutical compositions comprising ranitidine, alginic acid and a carbonate or bicarbonate
SE8803822D0 (sv) 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) † 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE4023028A1 (de) * 1990-07-20 1992-01-23 Hoechst Ag Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3142919B2 (ja) 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5229137A (en) † 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
JPH07509702A (ja) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
CA2110313C (en) † 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
AU7218294A (en) † 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
WO1995001795A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
WO1995008332A1 (en) 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
DE69430921T2 (de) † 1993-10-12 2003-02-13 Mitsubishi Pharma Corp Darmlösliche grannulatkörner enthaltende tablette
GB2285989A (en) 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2316333T3 (es) 1994-07-08 2009-04-16 Astrazeneca Ab Forma de dosificacion en tabletas constituida por unidades multiples.
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
DE69614097T2 (de) 1995-03-17 2002-03-14 Boots Co Ltd Flüssige pharmazeutische zusammensetzungen mit pektin
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1998023272A1 (en) 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
BR9607350A (pt) 1997-12-30
TR199700916T1 (xx) 1997-12-21
CN1183047A (zh) 1998-05-27
CN1080125C (zh) 2002-03-06
PL187075B1 (pl) 2004-05-31
DE69624907T3 (de) 2010-01-14
DE69624907T2 (de) 2003-08-21
SK283695B6 (sk) 2003-12-02
EP0813424A1 (en) 1997-12-29
AU712669B2 (en) 1999-11-11
BR9607350B1 (pt) 2010-08-10
SK116997A3 (en) 1998-05-06
NO974071D0 (no) 1997-09-04
SE9600071D0 (sv) 1996-01-08
IL121651A0 (en) 1998-02-08
CA2213996C (en) 2006-08-29
EG23821A (en) 2007-09-19
SA97170553B1 (ar) 2006-06-04
TW464514B (en) 2001-11-21
ATE228009T1 (de) 2002-12-15
NO974071L (no) 1997-10-17
EP0813424B2 (en) 2009-08-05
CZ293583B6 (cs) 2004-06-16
DK0813424T4 (da) 2009-11-09
US6183776B1 (en) 2001-02-06
EE04002B1 (et) 2003-04-15
HU229153B1 (en) 2013-09-30
CA2213996A1 (en) 1997-07-17
NO326656B1 (no) 2009-01-26
EP0813424B1 (en) 2002-11-20
AU1324197A (en) 1997-08-01
ZA9610935B (en) 1997-07-08
KR19980702829A (ko) 1998-08-05
HK1001763A1 (en) 1998-07-10
HUP9904024A3 (en) 2002-03-28
DE69624907D1 (de) 2003-01-02
EE9700192A (et) 1998-02-16
IL121651A (en) 2003-05-29
CZ274797A3 (cs) 1998-03-18
ES2185817T5 (es) 2009-11-24
JPH11501950A (ja) 1999-02-16
UA45392C2 (uk) 2002-04-15
WO1997025066A1 (en) 1997-07-17
IS4548A (is) 1997-08-20
HUP9904024A2 (hu) 2000-05-28
AR005281A1 (es) 1999-04-28
RU2179453C2 (ru) 2002-02-20
MY116091A (en) 2003-11-28
HK1017992A1 (en) 1999-12-10
PL322175A1 (en) 1998-01-19
KR100490075B1 (ko) 2005-09-08
IS2716B (is) 2011-02-15
NZ325977A (en) 1999-02-25
PT813424E (pt) 2003-03-31
DK0813424T3 (da) 2003-03-10
ES2185817T3 (es) 2003-05-01

Similar Documents

Publication Publication Date Title
MX9706785A (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
MY119212A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
CA2186039A1 (en) New oral pharmaceutical dosage form
CA2214027A1 (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
MX9600857A (es) Forma de dosificacion i en tabletas, con unidades multiples.
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
IS4329A (is) Fjöleiningaskammtar í töfluformi sem innihalda prótónupumpublokkara
DE69636104D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern
EE05670B1 (et) Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
CA2622805A1 (en) Compressed tablets comprising valsartan
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
WO1995022974A3 (en) Film coated tablet of paracetamol and domperidone
ES2198195A1 (es) Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
CA2408633A1 (en) Management of snoring by oral administration of dimethyl sulfone
EP1136492A4 (en) SULFAMIDE COMPOUNDS AND USES THEREOF AS MEDICAMENTS
BG106342A (en) Low-dose tablets and preparation method
EP1099439A3 (en) Use of apo B secretion/MTP inhibitors
WO2002069968A8 (en) New use
WO2002022171A3 (en) Pharmaceutical composition having specific water activity
EP0974361A4 (en) METHOD OF USING AN ANTI-ACID AGENT AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
CA2267503A1 (en) Methods and compositions for preventing and treating heartburn
JO1881B1 (en) Formula II for multi unit disc calibration
JO1880B1 (en) Format 1 for multi-unit calibration discs
JO1843B1 (en) Benzimercool vehicles carry alternatives and processes for their preparation and use in a pharmacy

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
HC Change of company name or juridical status

Owner name: MJN U.S. HOLDINGS LLC

MM Annulment or lapse due to non-payment of fees